RxDoctor Payments Data

Betty Morehead, NP

Family · Shelby, NCNPI 1033189253

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 111 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$362
  • AstraZeneca$339
  • Boehringer Ingelheim$192
  • Kowa Pharmaceuticals America, Inc.$145
  • Novo Nordisk$135
  • Johnson & Johnson$103
  • plus $459 from 9 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,734 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$131,089
Medicare patients
113
Services billed
3,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$60,958
MounjaroTirzepatide20$53,305
XareltoRivaroxaban31$28,588
EliquisApixaban16$20,169
FarxigaDapagliflozin Propanediol26$18,315
TradjentaLinagliptin14$17,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,112
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$9,497
Tresiba Flextouch U-100Insulin Degludec11$5,374
Saxagliptin Hcl12$4,138
Atorvastatin Calcium331$2,667
LantusInsulin Glargine,hum.Rec.Anlog15$2,534
SynthroidLevothyroxine Sodium21$2,275
Omeprazole110$1,941
Gabapentin134$1,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$60,95852 claims
Lilly USA, LLCMounjaro$96$53,30520 claims
Johnson & JohnsonXarelto$103$28,58831 claims
PfizerEliquis$50$20,16916 claims
AstraZenecaFarxiga$339$18,31526 claims
Boehringer IngelheimTradjenta$192$17,70314 claims
GSKTrelegy Ellipta$58$17,11218 claims
AbbVieSynthroid$362$2,27521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →